Abl (H396P), active

N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the H396P mutation. The Abl tyrosine kinase inhibitor STI571 (Gleevec™) is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse, due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the H396P mutation, which confers resistance to drug binding due to steric interference. (Corbin AS. et al, Blood, (2002); 101:4611-4614 and La Rosee P. et al, Cancer Research; 62:7149-7153).

Catalog No. Size Price Quantity
14-750M 250 µg $2466.85
14-750 10 µg $305.91

For account specific pricing, please contact Customer Service at customerservicedrx@eurofins.com.

Related Family Members:

Target
Abl
Expression System
Expressed by baculovirus in Sf21 insect cells
Application
Kinase Assay
Molecular Weight
121kDa
Accession Number
U07563
Species
Human
Tag
6His
Purification Method
Ni2+/NTA-agarose
Content
Protein in 50mM Tris/HCl pH7.5, 150mM NaCl, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij 35. Frozen solution.
Storage
6 months at -70°C
Bulk Sizes
Inquire